Abstract
Several cross-sectional studies have reported a relationship between elevated serum activity of liver enzymes [e.g. alanine aminotransferase (ALT) and gamma-glutamyltransferase (γGT)] and metabolic syndrome (MetS) and/or diabetes mellitus (DM). Raised serum activity of liver enzymes independently predicted the future development of MetS and DM as well as cardiovascular (CV) events and/or total/CV mortality in prospective studies. However, this association was not consistently demonstrated and it appears to be independent of alcohol intake. Even though these associations can be partly attributed to non-alcoholic fatty liver disease (NAFLD) and insulin resistance, there may be additional underlying mechanisms that contribute to the increased CV risk (e.g. inflammation and oxidative stress). The association of γGT with atherosclerotic plaque is of particular importance. The present review considers the link between serum liver enzyme activities and vascular risk. The links with DM and MetS are also discussed.
Keywords: Liver enzyme, alanine aminotransferase, gamma-glutamyltransferase, aspartate aminotransferase, non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular risk, metabolic syndrome, diabetes mellitus, atherosclerotic plaque
Current Pharmaceutical Design
Title: Liver Enzymes: Potential Cardiovascular Risk Markers?
Volume: 17 Issue: 33
Author(s): Eirini Lioudaki, Emmanuel S. Ganotakis and Dimitri P. Mikhailidis
Affiliation:
Keywords: Liver enzyme, alanine aminotransferase, gamma-glutamyltransferase, aspartate aminotransferase, non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular risk, metabolic syndrome, diabetes mellitus, atherosclerotic plaque
Abstract: Several cross-sectional studies have reported a relationship between elevated serum activity of liver enzymes [e.g. alanine aminotransferase (ALT) and gamma-glutamyltransferase (γGT)] and metabolic syndrome (MetS) and/or diabetes mellitus (DM). Raised serum activity of liver enzymes independently predicted the future development of MetS and DM as well as cardiovascular (CV) events and/or total/CV mortality in prospective studies. However, this association was not consistently demonstrated and it appears to be independent of alcohol intake. Even though these associations can be partly attributed to non-alcoholic fatty liver disease (NAFLD) and insulin resistance, there may be additional underlying mechanisms that contribute to the increased CV risk (e.g. inflammation and oxidative stress). The association of γGT with atherosclerotic plaque is of particular importance. The present review considers the link between serum liver enzyme activities and vascular risk. The links with DM and MetS are also discussed.
Export Options
About this article
Cite this article as:
Lioudaki Eirini, S. Ganotakis Emmanuel and P. Mikhailidis Dimitri, Liver Enzymes: Potential Cardiovascular Risk Markers?, Current Pharmaceutical Design 2011; 17 (33) . https://dx.doi.org/10.2174/138161211798220945
DOI https://dx.doi.org/10.2174/138161211798220945 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Herbal Oils for Treatment of Chronic and Diabetic Wounds: A Systematic Review
Current Diabetes Reviews Update on Pharmacologic Approaches to Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Current Vascular Pharmacology Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Calcium and Vitamin D Signaling in the Epidermal Response to Wounding
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Predominant microRNAs in β-cell Clusters for Insulin Regulation and Diabetic Control
Current Drug Targets Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines
Current Cardiology Reviews ABC Transporters in Neurological Disorders: An Important Gateway for Botanical Compounds Mediated Neuro-Therapeutics
Current Topics in Medicinal Chemistry Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Antidiabetic Activity of Dihydropyrimidine Scaffolds and Structural Insight by Single Crystal X-ray Studies
Medicinal Chemistry Strategies for Enhancing Progenitor Cell Mobilization and Function in Diabetes
Current Vascular Pharmacology MicroRNAs in Arterial Hypertension
Current Topics in Medicinal Chemistry Vasospastic Angina and Ca Channel Blockers
Current Hypertension Reviews Cystic Fibrosis Related Diabetes Mellitus - Diagnostic and Management Challenges
Current Diabetes Reviews The Evidence Base for Revascularisation of Chronic Total Occlusions
Current Cardiology Reviews Molecular Imaging of Diabetic Pancreas
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes
Current Vascular Pharmacology Immunosuppression in Liver Transplantation
Current Drug Targets Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued) Endoplasmic Reticulum Stress, Diabetes Mellitus, and Tissue Injury
Current Protein & Peptide Science